<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE GlossaryTerm >
<GlossaryTerm id="CDR0000754339"><TermName>obinutuzumab</TermName><TermPronunciation>(OH-bin-yoo-TOO-zoo-mab)</TermPronunciation><TermDefinition><DefinitionText>A drug used with another drug to treat chronic lymphocytic leukemia (CLL) that has not already been treated. It is also being studied in the treatment of other types of cancer. Obinutuzumab binds to a protein called CD20, which is found on B cells (a type of white blood cell) and some types of leukemia cells. This may help the immune system kill cancer cells. Obinutuzumab is a type of monoclonal antibody. Also called Gazyva.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></TermDefinition><MediaLink ref="CDR0000757931" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;obinutuzumab&quot;" language="en" id="_3"/><MediaLink ref="CDR0000757930" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;obinutuzumab&quot;" language="es" id="_4"/><SpanishTermName>obinutuzumab</SpanishTermName><SpanishTermDefinition><DefinitionText>Medicamento que se usa con otro medicamento para tratar la leucemia linfocítica crónica (LLC) que no se ha sometido a tratamiento. También está en estudio para el tratamiento de otros tipos de cáncer. El obinutuzumab se une a una proteína que se llama CD20, que se encuentra en las células B (un tipo de glóbulo blanco) y en algunos tipos de células leucémicas. Puede ayudar al sistema inmunitario a destruir células cancerosas. El obinutuzumab es un tipo de anticuerpo monoclonal. También se llama Gazyva.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></SpanishTermDefinition><DateFirstPublished>2013-11-12</DateFirstPublished><RelatedInformation><RelatedDrugSummaryRef href="CDR0000754305">Obinutuzumab</RelatedDrugSummaryRef></RelatedInformation></GlossaryTerm>
